Navigation Links
AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Date:11/13/2008

for the three-month period ended September 30, 2008 compared to the same period last year, is mainly related to the advancement of the cetrorelix Phase 3 program for BPH, lower manufacturing margins and foreign exchange loss.

The cash and short-term investments were $11 million as at September 30, 2008.

CONFERENCE CALL

Management will be hosting a conference call for the investment community beginning at 10:00 a.m. Eastern Time, today, November 13, 2008, to discuss third quarter 2008 financial results. To participate in the live conference call by telephone, please dial 416-646-3095, 514-807-8791 or 800-814-4859. Individuals interested in listening to the conference call on the Internet may do so by visiting http://www.aezsinc.com. A replay will be available on the Company's Web site for 30 days.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Inves
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
2. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
4. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
5. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
6. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
8. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
9. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
10. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
11. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- BioNano Genomics, Inc., the leader in genome mapping, announced ... commercial officer. Salyer has more than 20 years of ... sciences. At BioNano, Salyer will oversee the commercialization of ... assemble a comprehensive view of complex genomes to help ... located in the United States , ...
(Date:3/26/2015)... 26, 2015 "In America," the popular news ... States that is hosted by legendary film actor James Earl ... botany in an upcoming segment. , Botany is commonly ... it is actually quite a bit more complicated than that. ... types of living organisms, from the smallest bacteria known to ...
(Date:3/25/2015)... March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... a result of recent discussions with certain shareholders representing ... the Company, after dealing with certain matters including the ... of shareholders on March 26, 2015 (the "Meeting") it ... of directors will take place when the Meeting reconvenes. ...
(Date:3/25/2015)... , March 25, 2015 Accelovance, a therapeutically ... finalist for "Best Contract Research Organization" at the upcoming ... Vaccine Congress. This is the eighth ... for the award, winning for "Best Contract Research Organization" ... Recommended" distinction in 2013. "We,re excited to ...
Breaking Biology Technology:BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2
... Genomatica announced today that William ... time as executive chairman and chief business development officer. ... producers, users, feedstock suppliers, brands and retailers.   ... $500 million in partnerships Bill brings ...
... Genetic Risk Factor for the Most Common Form of... -- REYKJAVIK, Iceland, September 13, 2010 ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... MOUNTAIN VIEW, Calif., Sept. 10 VIVUS, Inc. (Nasdaq: ... will present an overview of the company at four ... presentation schedule is as follows:Bank of America Merrill Lynch ... officerSeptember 16, 2010 at 2:30 p.m. BST Bank of ...
Cached Biology Technology:Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 2Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 3Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 4deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 2deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 3deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 4deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 5deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 6deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 7deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 8VIVUS to Present at Four Upcoming Investor Conferences 2
(Date:3/24/2015)... 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands by the following Segments: Face Biometrics, and ... Canada , Japan , ... Middle East & Africa , and ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... March 23, 2015   HOYOS Labs , a ... today announced that the Company will demonstrate multiple biometrics-based ... and consumers at Connect:ID on March 23 through 25, ... Labs will highlight the IEEE Biometric Open Protocol Standard; ... and enterprise access control system. BOPS was invented by ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... SAN FRANCISCO, FEB. 10, 2011 -- Research presented today ... Medicine (SMFM) -- The Pregnancy Meeting has found that three ... part for the success of progesterone treatments in the prevention ... role in triggering normal labor. The proteins ...
... that we know everything about how the flea jumps, ... store the energy needed to catapult themselves into the ... in the intervening years debate raged about exactly how ... came up with competing hypotheses, but neither had access ...
... groups of lowly marine worms are related to complex species ... research. Previously thought to be an evolutionary link between simple ... - the worms, surprising promotion implies that they have not ... the marine worms Xenoturbella and Acoelomorpha ...
Cached Biology News:New research helps explain how progesterone prevents preterm birth 244-year-old mystery of how fleas jump resolved 244-year-old mystery of how fleas jump resolved 3Simple marine worms distantly related to humans 2
... Serum-free adapted Sf9 derivative for high-yield protein ... Cells are derived from a high-yielding clone ... Novagen serum-free TriEx Insect Cell Medium, these ... protein yields by either baculovirus infection or ...
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Biology Products: